Fig. 1

PGAM5 expression is altered in human and mice NASH models. a–d Identical IHC of PGAM5 in human liver sections with different stages of NASH (a healthy donor; b steatosis without fibrosis; c steatosis with fibrosis stage 1–2; d steatosis with fibrosis stage 3–4). Scale bars, 50 μm. e, f Hepatic PGAM5 protein levels in mice fed with CON and HFD for 20 weeks. *p < 0.05. N = 5. g, h Hepatic PGAM5 protein levels in wild type mice fed with CON for 20 weeks, HFHF for 12 weeks, MCS and MCD for 6 weeks. *p < 0.05 compared with CON, ^#p < 0.05 compared with HFHF, ^&p < 0.05 compared with MCS. N = 5–12. i–k Representative pictures of hepatic double immunofluorescence staining for PGAM5 (red) and albumin (green)/F4/80 (green) and α-SMA (green) in wildtype fed on CON, HFHF, MCS or MCD diet. Nuclei were stained by DAPI. IHC, immunohistochemistry; CON, control diet; HFD, high fat diet; HFHF, high fat high fructose; MCS, methionine choline supplemented; MCD, methionine choline deficient